Compare OCUL & AORT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | OCUL | AORT |
|---|---|---|
| Founded | 2006 | 1984 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Medical/Dental Instruments |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.2B | 2.1B |
| IPO Year | 2014 | 1993 |
| Metric | OCUL | AORT |
|---|---|---|
| Price | $9.11 | $39.90 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 10 | 5 |
| Target Price | $22.56 | ★ $49.36 |
| AVG Volume (30 Days) | ★ 6.1M | 317.1K |
| Earning Date | 02-05-2026 | 02-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | $51,951,000.00 | ★ $422,646,000.00 |
| Revenue This Year | $20.43 | $15.97 |
| Revenue Next Year | $79.81 | $10.96 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 9.81 |
| 52 Week Low | $5.79 | $21.97 |
| 52 Week High | $16.44 | $48.25 |
| Indicator | OCUL | AORT |
|---|---|---|
| Relative Strength Index (RSI) | 36.76 | 34.89 |
| Support Level | $8.36 | $39.08 |
| Resistance Level | $9.69 | $41.00 |
| Average True Range (ATR) | 0.67 | 1.31 |
| MACD | -0.01 | -0.09 |
| Stochastic Oscillator | 27.37 | 16.32 |
Ocular Therapeutix Inc is a biotechnology company that specializes in therapies for diseases and conditions of the eye. The company uses its proprietary hydrogel platform technology to deliver therapeutic agents to the eye. Its pipeline consists of eye medication that aims to overcome the limitations of current eye-drop-based therapies for ophthalmic diseases and conditions. Its pipeline product includes Dextenza, OTX-TIC, OTX-TKI, and OTX-IVT.
Artivion Inc offers cardiac and vascular surgeons a suite of aortic-centric solutions. The company's products include Aortic Heart Valve, Mitral Heart Valve, Aortic Allograft, Pulmonary Human Heart Valve, Pulmonary Patch, and Surgical Adhesive among others. The company's has two reportable segments: Medical Devices and Preservation Services. The Medical Devices segment includes revenues from sales of aortic stent grafts, surgical sealants, On-X products, and other product revenues. The Preservation Services segment includes services revenues from the preservation of cardiac and vascular implantable human tissues. Company operates in North America, EMEA. LATAM, APAC. Maximum revenue is from North America.